Ezra Y. Rosen

Oncology
300 E 66th St
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications

Beyond Tolerability: Putting Efficacy at the Center of Radiotherapy-Drug Dose Optimization.

Beyond Tolerability: Putting Efficacy at the Center of Radiotherapy-Drug Dose Optimization.

Journal: International journal of radiation oncology, biology, physics
Published: July 21, 2026

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

Journal: Cancer cell
Published: April 19, 2026

The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid Tumors.

The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 17, 2025

PTCH1 mutations and tumor-agnostic clinical outcomes with hedgehog pathway inhibitors across cancer types.

PTCH1 mutations and tumor-agnostic clinical outcomes with hedgehog pathway inhibitors across cancer types.

Journal: NPJ precision oncology
Published: November 03, 2025

Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial.

Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 29, 2025

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 21, 2025

Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.

Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 23, 2025

Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response-Deficient Tumors.

Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response-Deficient Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 14, 2025

The cold immunological landscape of ATM-deficient cancers.

The cold immunological landscape of ATM-deficient cancers.

Journal: Journal for immunotherapy of cancer
Published: April 01, 2025

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.

Journal: bioRxiv : the preprint server for biology
Published: May 20, 2024

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

Journal: Cancer cell
Published: April 26, 2024

Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer.

Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer.

Journal: NPJ precision oncology
Published: January 31, 2024
Showing 1-12 of 34

Last Updated: 09/26/2026